1513883-39-0
Chemical Structure
Deuruxolitinib
Synonym(s): CTP-543;Ruxolitinib d8;Deuterated Ruxolitinib
- CAS No.: 1513883-39-0
- Formula:C17H10D8N6
- Molecular Weight:314.41
IUPAC Name: (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyclopentyl-2,2,3,3,4,4,5,5-d8)propanenitrile
InChIKey: HFNKQEVNSGCOJV-FBXGHSCESA-N
SMILES: N#CC[C@@H](N1N=CC(C2=C3C(NC=C3)=NC=N2)=C1)C4C([2H])(C([2H])(C([2H])(C4([2H])[2H])[2H])[2H])[2H]
Biological Activity: Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and JAK2 inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deuruxolitinib | 99.18% | Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and JAK2 inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ruxolitinib (Standard) | 99.74% | Ruxolitinib (Standard) is the analytical standard of Ruxolitinib. This product is intended for research and analytical applications. Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ruxolitinib-d9 | Ruxolitinib-d9 (INCB18424-d9) is deuterium labeled Ruxolitinib. Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ruxolitinib | 99.90% | Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
